Central muscarinic control of the pattern of small intestinal motility in XXXX .

@entity4138 @entity1139 @entity5592 @entity4140 @entity3897 @entity35
The effects of central and peripheral administration of muscarinic agonists and antagonists on small intestinal motility were examined in conscious @entity35 chronically fitted with electrodes implanted in the duodeno-jejunal wall and a cannula in a cerebral lateral ventricle. Intracerebroventricular (i.c.v.) administration of either @entity3897 or @entity4140 at doses from 1 to 10 micrograms, 15 min before a 3 and 6 g lab chow meal significantly reduced the duration of the postprandial disruption of the migrating myoelectric complexes ( @entity1139 ). The reduction was significantly greater for @entity3897 , a mixed M1 and M2 muscarinic receptor antagonist, than for @entity4140 , an antagonist with a high affinity for M1 receptors. At a higher dose (10 micrograms) intra peritoneal (i.p.) administration of @entity3897 or @entity4140 did not modify the postprandial disruption of @entity1139 . @entity5592 (10 ng) a M2 agonist, but not @entity4138 (5 micrograms), a selective M1 agonist, given i.c.v. in fasted @entity35 disrupted for 1.5 h the @entity1139 pattern. At the same doses given i.p. @entity5592 and McNeil A343 disrupted the @entity1139 for 15 and 45 min respectively. We conclude that the postprandial changes in the small intestinal motility involve muscarinic receptors, mainly of M2 subtype, at the level of the central nervous system.
